【参考文献】
[ 1 ] Agarwal R. Statin induced p roteinuria: renal injury or renop rotection[ J ].J Am Soc Nephrol, 2004, 15 (2) : 2502.
[ 2 ] Avram MM, Bonomini LV, Sreedhara R, et al. Predictive value of nutritional markers ( albumin, creatinine, cholesterol, and hematocrit) for patients on dialysis for up to 30 years [ J ]. Am J Kidney Dis, 1996, 28(6) : 9102917.
[ 3 ] Baigent C,LandryM. Study of heart and renal p rotection ( SHARP) [ J ].Kidney Int Supp l, 2003, 84 (4) : S2072210.
[ 4 ] Baigent C, LandrayM, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK2HARP2I) study: biochemical efficacy and safety of simvastatin and safety of low2dose asp irin in chronic kidney disease[ J ].Am J Kidney Dis, 2005, 45 (3) : 4732484.
[ 5 ] Bianchi S,Bigazzi R, Caiazza A, et al. A controlled, p rospective study of the effects of atorvastatin on p roteinuria and p rogression of kidney disease[ J ]. Am J Kidney Dis, 2003, 41 (3) : 5652570.
[ 6 ] Bocan TM. Pleiotrop ic effects of HMG2CoA reductase inhibitors[ J ]. CurrOp in Investig Drugs, 2002, 3 (9) : 131221317.
[ 7 ] Bonnie CH, Kwan FK, Srinivasan B, et al. Lipop rotein Metabolism and Lip idManagement in Chronic Kidney Disease [ J ]. J Am Soc Nephrol,2003, 18 (2) : 124621261.
[ 8 ] Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients [ J ]. Kidney Int, 2000, 58(1) : 3532362.
[ 9 ] Collins R,Armitage J, Parish S, et al. MRC /BHF Heart Protection Study of cholesterol2lowering with simvastatin in 5963 peop le with diabetes: arandomised p lacebo2controlled trial[ J ]. Lancet, 2003, 361 (5) : 2005.
[ 10 ]CressmanMD, Heyka RJ, Paganini EP, et al. Hoff HFLipop rotein ( a) isan independent risk factor for cardiovascular disease in hemodialysis patients[ J ]. Circulation, 1992, 86 (2) : 4752482.
[ 11 ]Culleton BF, Larson MG,Wilson PW, et al. Cardiovascular disease and mortality in a community2based cohort with mild renal insufficiency[ J ].Kidney Int, 1999, 56 (6) : 221422219.
[ 12 ]Davignon J. Beneficial cardiovascular p leiotrop ic effects of statins [ J ].
Circulation, 2004, 109 (23) : 11139211143.
[ 13 ]Deighan CJ, CaslakeMJ,McconnellM, et al. Atherogenic lipop rotein phenotype in end2stage renal failure: origin and extent of small dense lowdensity lipop rotein formation [ J ]. Am J Kidney Dis, 2000, 35 ( 5 ) : 8522862.
[ 14 ]Douglas K,O’Malley PG, Jackson JL. Meta2analysis: the effect of statins on albuminuria[ J ]. Ann InternMed, 2006, 145 (2) : 1172124.
[ 15 ] Ep steinM, Campese VM. Pleiotrop ic effects of 32hydroxy232methylglutaryl coenzyme a reductase inhibitors on renal function[ J ]. Am J KidneyDis,2005, 45 (1) : 2214.
[ 16 ] Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) . Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel Ⅲ)[ J ]. JAMA, 2001, 285 (19) : 248622497.
[ 17 ]Gardner CD, Fortmann SP, Krauss RM. Association of small low2density lipop rotein particleswith the incidence of coronary artery disease in men and women[ J ]. JAMA, 1996, 276 (11) : 8752881.
[ 18 ]Ghosh PM,Mott GE, Ghosh2ChoudhuryN, et al. Lovastatin induces apoptosis by inhibiting mitotic and post2mitotic events in cultured mesangial cells[ J ]. Biochim BiophysActa, 1997, 1359 (10) : 13224.
[ 19 ]Hahn R,Oette K,Mondorf H, et al. Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipop roteinemias[ J ]. Atherosclerosis, 1983 , 48 (3) : 2792288.
[ 20 ]Heart Protection Study Collaborative Group. MRC /BHF Heart Protection Study of antioxidant vitamin supp lementation in 20, 536 high2risk individuals[ J ]. Lancet, 2002, 360 (9326) : 23233.
[ 21 ]Heeringa P, Tervaert JW. Role of oxidized low2density lipop rotein in renal disease[ J ]. CurrOp in Nephrol Hypertens, 2002, 11 (3) : 2872293.
[ 22 ]Hernandez PO, Perez SD, Navarro AJ, et al. Effects of the 32hydroxy232 methylglutaryl2CoA reductase inhibitors, atorvastatin and simvastatin, on
the exp ression of endothelin21 and endothelial nitric oxide synthase in
vascular endothelial cells[ J ]. J Clin Invest, 1998, 101 (8) : 271122719.
[ 23 ] Iseki K, Yamazato M, Tozawa M, et al. Hypocholesterolemia is a significant p redictor of death in a cohort of chronic hemodialysis patients[ J ].Kidney Int, 2002, 61 (5) : 188721893.
[ 24 ] Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG2CoA reductase[ J ]. Science, 2001, 292 (5519) : 116021164.
[ 25 ] Kamanna VS, Kirschenbaum MA. Effect of low2density lipop roteins on mesangial cell exp ression ofmonocyte chemoattractant pep tides[ J ]. Contrib Nephrol, 1997, 120 (6) : 1762190.
[ 26 ]Kamanna VS, Pai R, Roh DD, et al. Oxidative modification of low2density lipop rotein enhances the murine mesangial cell cytokines associated with monocyte migration, differentiation, and p roliferation [ J ]. Lab Invest,1996, 74 (6) : 106721979.
[ 27 ]Kasiske BL. Hyperlip idemia in patients with chronic renal disease [ J ].Am J Kidney Dis, 1998, , 32 (5 Supp l 3) : S1422156.
[ 28 ]Kent SM, Flaherty PJ, Coyle LC. Effect of atorvastatin and p ravastatin on serum C2reactive p rotein[ J ]. Atherosclerosis, 2002, 164 (1) : 1792185.
[ 29 ]Kidney Disease OutcomesQuality Initiative (K/DOQ I) Group. K/DOQ Iclinical p ractice guidelines for management of dyslip idemias in patients with kidney disease[ J ]. Am J Kidney Dis, 2003, 41 ( 4 Supp l 3) : I2IV,S1291.
[ 30 ]Kimak E, Solski J. ApoA2 and apoB2containing lipop roteins and Lp ( a)concentration in non2dialyzed patientswith chronic renal failure[ J ]. RenFail, 2002, 24 (4) : 4852492.
[ 31 ]KochM, Kutkuhn B, Grabensee B, et al. Apolipop rotein A, fibrinogen,age, and history of stroke are p redictors of death in dialysed diabetic pa2tients: a p rospective study in 412 subjects[ J ]. NephrolDial Transp lant,1997, 12 (12) : 260322611.
[ 32 ]Kronenberg F,NeyerU,Lhotta K, et al. The low molecularweight apo ( a)phenotype is an independent p redictor for coronary artery disease in hemodialysis patients: a p rospective follow2up [ J ]. J Am Soc Nephrol, 1999, 10 (5) : 102721036.
[ 33 ] LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets( TNT)Investigators. Intensive lip id lowering with atorvastatin in patientswith stable coronary disease [ J ]. N Engl J Med, 2005, 352 ( 14) :142521435.
[ 34 ]Launay VV, Izzedine H, Deray G. Statinspdosage in patients with renalfailure and cyclosporine drug2drug interactions in transp lant recip ient patients. Int[ J ]. J Cardiol, 2005, 101 (1) : 9217.
[ 35 ]Lee HS, Jeong JY, Kim BC, et al. Dietary antioxidant inhibits lipop rotein oxidation and renal injury in experimental focal segmental glomerulosclerosis[ J ]. Kidney Int, 1997, 51 (4) : 115121159.
[ 35 ]Lemos PA, Serruys PW, de Feyter P, et al. Long2term fluvastatin reduces the hazardous effect of renal impairment on four2year atherosclerotic outcomes ( a L IPS substudy) [ J ]. Am J Cardiol, 2005, 95 (4) : 4452451.
[ 36 ]Li H,Li X,Duan L, et al. Inhibition of lovastatin on p roliferation and exp ression of p roinflammatory cytokines in cultured human glomerular mesangial cells[ J ]. ChinMed J ( Engl) , 2003, 116 (9) : 136621369.
[ 37 ]Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition[ J ]. JAMA, 2004, 291 (4) : 4512459.
[ 38 ]Mason NA, Bailie GR, Satayathum S, et al. HMG2coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients[ J ]. Am J Kidney Dis, 2005, 45 (1) : 1192126.
[ 39 ]Moorhead JF, ChanMK, El2NahasM, et al. Lip id nephrotoxicity in chronic p rogressive glomerular and tubulo2interstitial disease [ J ]. Lancet,1982, 2 (8311) : 130921311.
[ 40 ]Muntner P, He J,Astor BC, et al. Traditional and nontraditional risk factors p redict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study [ J ]. J Am Soc Nephrol,2005, 16 (2) : 5292538.
[ 41 ]Ness GC, Zhao Z,Lopez D. Inhibitors of cholesterol biosynthesis increase hepatic low2density lipop rotein recep tor p rotein degradation [ J ]. Arch Biochem Biophys, 1996, 325 (2) : 2422248.
[ 42 ]Nishizawa Y, Shoji T, Kakiya R, et al. Non2high2density lipop rotein cholesterol ( non2HDL2C) as a p redictor of cardiovascular mortality in patientswith end2stage renal disease[ J ]. Kidney Int Supp l, 2003, 63 (6) :234522346.
[ 43 ] The Long2Term Intervention with Pravastatin in Ischaemic Disease (L IPID) Study Group. Prevention of cardiovascular events and death withp ravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. [ J ]. N Engl J Med, 1998, 339 ( 19 ) : 134921357.
[ 44 ]Raggatt LJ, Partridge NC. HMG2CoA reductase inhibitors as immunomodulators: potential use in transp lant rejection [ J ]. Drugs, 2002, 62 ( 15) :
[ 45 ] ShinMK, Roh DD, Kamanna VS, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study ( 4S) [ J ]. Lancet, 1994, 344 ( 8934 ) : 138321389.
[ 46 ]Roh DD, Kamanna VS, Kirschenbaum AC, et al. MA Oxidative modification of low2density lipop rotein enhances mesangial cell p rotein synthesis and gene exp ression of extracellular matrix p roteins[ J ]. Am J Nephrol,1998, 18 (4) : 3442350.
[ 47 ]Ruan XZ,Varghese Z, Powis SH, et al. Dysregulation ofLDL recep tor under the influence of inflammatory cytokines: a new pathway for foam cellformation[ J ]. Kidney Int, 2001, 60 (5) : 171621725.
[ 48 ]Ruan XZ,Varghese Z, Fernando R, et al. Cytokine regulation of low2den2
sity lipop rotein recep tor gene transcrip tion in human mesangial cells[ J ].
Nephrol Dial Transp lant, 1998, 13 (6) : 139121397.
[ 49 ]Ruan XZ,Moorhead JF, Fernando R, et al. Regulation of lipop rotein trafficking in the kidney: role of inflammatory mediators and transcrip tionfactors[ J ]. Biochem Soc Trans, 2004, 32 (9) : 88291.
[ 50 ] Shulman NB, Ford CE, HallWD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Resultsfrom the hypertension detection and follow2up p rogram [ J ]. Hyperten2sion, 1989, 13 (5) : I802193.
[ 51 ] Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: across2sectional study[ J ]. J Am Soc Nephrol, 2001, 12 (7) : 151621523.
[ 52 ] Sabrina S,NatashaW, Linda FF, et al. Statins for Imp roving Renal Outcomes. A Meta2Analysis [ J ]. J Am Soc Nephrol, 2006, 17 ( 4 ) : 2012206.
[ 53 ] Sacks FM, PfefferMA,Moye LA, et al. The effect of p ravastatin on coronary events aftermyocardial infarction in patientswith average cholesterollevels.Cholesterol and Recurrent Events Trial investigators[ J ]. N Engl JMed, 1996 , 335 (14) : 100121009.
[ 54 ] Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthymen[ J ]. J Am Soc Nephrol, 2003,14 (2) : 2084.
[ 55 ] Seliger SL,WeissNS, Gillen DL, et al. HMG2CoA reductase inhibitors are
associated with reduced mortality in ESRD patients [ J ]. Kidney Int,
2002, 61 (1) : 2972304.
[ 56 ] Sever PS,DahlofB, PoulterNR, et al. ASCOT investigators. Prevention of coronary and stroke eventswith atorvastatin in hypertensive patients who have average or lower2than2average cholesterol concentrations, in the Anglo2Scandinavian Cardiac Outcomes Trial22Lip id LoweringArm (ASCOT2LLA) : a multicentre randomised controlled trial[ j ]. Lancet, 2003, 361(9364) : 114921158.
[ 57 ] Steinmetz OM, Panzer U, Stahl RA, et al. Statin therapy in patients with chronic kidney disease: to use or not to use[ J ]. Eur J Clin Invest, 2006,36 (8) : 5192527.
[ 58 ] TonelliM, Moye L, Sacks FM, et al. Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary p revention of cardiovascular events in persons with mild chronic renal insufficiency[ J ].Ann InternMed, 2003, 138 (2) : 982104.
[ 59 ] TonelliM, Isles C, Curhan GC, et al. Effect of p ravastatin on cardiovascular events in peop le with chronic kidney disease [ J ]. Circulation,2004, 21; 110 (12) : 155721563.
[ 60 ] TonelliM, Keech A, Shepherd J, et al. Effect of p ravastatin in peop lewith diabetes and chronic kidney disease [ J ]. J Am Soc Nephrol, 2005;16 (12) : 374823754.
[ 61 ] TonelliM, Moye L, Sacks FM, et al. Cholesterol and Recurrent EventsTrial Investigators. Effect of p ravastatin on loss of renal function in peop le with moderate chronic renal insufficiency and cardiovascular disease[ J ]. J Am Soc Nephrol, 2003, 14 (6) : 160521613.
[ 62 ]Vaziri ND. Dyslip idemia of chronic renal failure: the nature, mechanisms, and potential consequences [ J ]. Am J Physiol Renal Physiol,2006, 290 (2) : F2622272.
[ 63 ]Wagner AH, Ruckschloss TK, Just I. Imp rovement of nitric oxide2dependent vasodilatation by HMG2CoA Reductase inhibitors through attenuation of endothelial superoxide anion formation [ J ]. Arteio Thromb Vas2cular, 2000, 20 (6) : 61268
[ 64 ]Wanner C, Krane V, Marz W, et al. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis[ J ]. N Engl J Med, 2005, , , 353 (3) : 2382248.
[ 65 ]WeinerDE, SarnakMJ. Managing dyslip idemia in chronic kidney disease[ J ]. J Gen InternMed, 2004, 19 (10) : 104521052.
[ 66 ]宋红梅,李学旺. 魏珉. 高脂饮食对阿霉素肾病大鼠肾小球系膜基质的影响[ J ]. 中国医学科学院学报, 2000, 22 (5) : 47024751

来源：实用医院临床杂志   作者：李学旺 李航 张国娟